Childhood obesity has quadrupled since the 1960s. Now over 20% of kids meet the definition (>95th percentile of BMI). This is driving type 2 diabetes in children, and increases the risk of other diseases as adults. We need to talk about weight-loss drugs for kids. 🧵

In this video, Professor Dominique Guerrot presents the DAPA-PKD study, a collaborative research effort he co-leads with Professor Emilie Cornec-Le Gall (Brest). This important study will evaluate the potential of SGLT2 inhibitors, such as dapagliflozin, in the treatment of #ADPKD.

Tonight it's all about ADPKD! KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller youtu.be/qjnYDsYbx0Q?... @rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social

I have a feeling sales of home blood pressure cuffs are going to spike because people working in Primary Care like myself are going to be telling patients to confirm what the Apple watch is telling them with an actual blood pressure cuff.

🧵How to write and manage your first research budgets The point of funding is to convert it into quality research. A well-spent research budget should fund the idea it was raised on, plus revision experiments, plus preliminary data for the next grant. So you need to spend, while avoiding waste.

📚 The 2025 #KDIGO Guidelines recommend ambitious BP targets to manage hypertension in ADPKD: 🎯 ≤110/75 mmHg (HBPM) for adults <50 y with preserved renal function (G1–G2), 🎯 <120 mmHg systolic (office BP) in older adults, if tolerated.

#NephrOdio podcasts 🎧 🚀 Half a million downloads !

New 2025 AHA/ACC Hypertension Guideline dropped! www.jacc.org/doi/10.1016/... #hypertension #medsky #nephsky

CONFIDENCE trial: For patients with both chronic kidney disease and type 2 diabetes, whether combination therapy with finerenone and empagliflozin would improve outcomes over single-drug therapy is unclear. Research findings are summarized in a new Quick Take video. nej.md/40Szhuy

In the introduction, @johngreensbluesky.bsky.social drops some TB facts Annually more than a million people die of TB Overall, more than a *billion* people have died of TB in last 2 centuries That’s also something like 1 in 7 people who have ever lived 🤯 #NephJCBookClub

🫀 #Hypertension in autosomal dominant polycystic kidney disease: unique pathways, common consequences. In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease. Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵

should we screen for CKD in the general population? Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case www.nephjc.com/news/2025/7/... for #NephJC shorts Time to stop just being dialysis-ologists and flozinate, glipinate! #NephSky

Awesome infographic on genetic testing in ADPKD by Neera Dahl, @pranavgarimella.bsky.social and Fouad Chebib www.kidneynews.org/view/journal...

"The suburbia of Rouen" @dguerrot.bsky.social

Watch our next stop on YouTube: Diagnosis of Allograft Rejection Today & Tomorrow - Dr. Olivier Aubert, Dr. Aylin Akifova @olivieraubert.bsky.social @aylinink.bsky.social youtu.be/cqe3R3Q9B4Y?...

❓ Can we measure #bloodpressure in the arm with a closed AV #fistula after kidney transplant? ✅ YES! Here is our our latest study published in Hypertension @ahajournals.bsky.social showing no significant BP difference between arms post-AVF closure 👉🏼 www.ahajournals.org/doi/10.1161/...

Our second stop (Tour Academique): Update PD: Focus Assisted PD & Anticoagulation - Prof. T. Lobbedez & Dr. C. Béchade (Caen, France) @lobbedezt.bsky.social @clemencebechade.bsky.social youtu.be/rLO1X7sBILc?...

It's Tour Académique time again! Our first stop: Imlifidase in Highly Sensitized Allograft Recipients - Dr. Dominique Bertrand (Rouen, France) youtu.be/4xWzaXn0o8w?...

On est parti ! #TourAcadémique2025 @dgfn.bsky.social @oegn.bsky.social @sfndt.bsky.social @dguerrot.bsky.social youtube.com/watch?v=4xWz...

📅Tour Académique 2025 from 4th-25th July: French, German & Austrian nephrologists will present current research & practical topics relating to renal medicine.Topics: AKI after Glyoxylic Acid for Hair-Straightening | Update PD /Imlifidase in Highly Sensitized Allograft Recipients etc.

Join us for our Grand Départ on Friday Evening! 🙏 to @dguerrot.bsky.social for co-chairing notre #TourAcadémique 2025 @markusathome.bsky.social

#TourAcadémique2025 Proud to announce this year's line-up together with @dguerrot.bsky.social @dgfn.bsky.social @oegn.bsky.social @sfndt.bsky.social youtu.be/dK4NO5TTKl4?...

And live at NEJM www.nejm.org/doi/full/10.... Trial from Ottawa at #CCR25 Really, who still cares about balanced versus normal saline arguments! (Beyond some nerdy nephrons and Josh)

In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: nej.md/4jEVbbk #ERA25 #MedSky #Nephrology

N'hésitez plus... inscrivez vous au 𝗗𝗣𝗖 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗲 𝗿𝗲́𝗻𝗮𝗹𝗲 & 𝗛𝗧𝗔 🏃‍♀️‍➡️ 🗓️ 19 & 20/06, les après-midis, en classe virtuelle Inscription jusqu'au 18/06 Programmes et inscription ➡️ apfcn.fr #formation #sante #nephrologie #physiologie #hta @sfndt.bsky.social

This is such a great resource: www.kidney-international.org/article/S008... #nephrology #eGFR

Promising! flozination in ADPKD (mostly older adults with DM or CVD) - presumably those with another valid indication - associated with slower GFR slope journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social #CJASN With no obvious harm signal

#1 Today is World HTN Day! 🧑‍🤝‍🧑1.3 billion people live with HTN, but only 1 in 5 meet BP goals. ⚠️HTN silently drives stroke, heart & kidney failure—and 57% of global deaths. Check this beautiful Infographic by @gabyneph.bsky.social #ISNTweetorial #WorldHypertensionDay

More on BEDMED: youtu.be/mqkTYElw0fo?... With @rickyturgeon.bsky.social Dr. Scott Garrison @hswapnil.medsky.social and Dr. Isla Mackenzie @markusathome.bsky.social

There you have it: BEDMED published in @jama.com jamanetwork.com/journals/jam... h/t @drjmluther.bsky.social No difference in bedtime versus morning BP meds - as expected #NephSky #Hypertension 1/

Amiloride was noninferior to spironolactone in lowering home systolic blood pressure at 12 weeks. https://ja.ma/42XMGD9

In the Advance-HTN trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results and Research Summary: nej.md/4ipbCIf #MedSky #CardioSky

Vous aimez pas la spironolactone, essayez alors l'amiloride pour les HTA résistantes, la science de la non infériorité est avec vous. jamanetwork.com/journals/jam...

The ASIs have arrived www.nejm.org/doi/full/10.... Aldosterone synthase inhibitors - first one to finish the phase 3 line #Lorundrostat #Hypertension

1/10 We were delighted to discuss the first ever @KDIGO ADPKD guidelines this March! So satisfied with the chat itself that we forgot to post the #TenPostsNephJC 😉 So here we are! Better late than never.#NephJC kdigo.org/guidelines/a...

In the @annalsofim.bsky.social www.acpjournals.org/doi/10.7326/... from @ucalgarymed.bsky.social team Saline suppression test not useful in confirming primary #aldosteronism - go straight to AVS if planning Sx (and ramp up MRA to target renin if Medical management) #NephSky #EndoSky

💻 How are future doctors learning today? A study of 1st-year MBBS students reveals a blend of textbooks & digital tools, with Wikipedia & mobile internet leading the charge.🚀 Challenges? Slow speeds & trust issues! 🔗 pmc.ncbi.nlm.nih.gov/articles/PMC12011279/ 🔎 #MedEd #DigitalLearning #DHPSP

Renal Denervation in Loin Pain Hematuria Syndrome: A Pilot Randomized Controlled Trial bit.ly/PrasadRL25 (FREE)

For patients with lupus nephritis, a recent phase 2 trial showed that the addition of obinutuzumab to standard therapy was associated with a significantly better renal response than placebo. Findings of the REGENCY phase 3 trial are summarized in a new Quick Take video. youtu.be/cqu42EDvPq8 #MedSky

Pfizer gives up on their oral GLP1RA danuglipron - concerns about liver toxicity (N of 1 with reversible severe injury) #MedSky www.businesswire.com/news/home/20...

STOP-PKD, DAPA-PKD and EMPA-PKD will indeed deliver long awaited crucial data towards implementation of SGLT2i in ADPKD. Looking forward to discussing these trials @markusathome.bsky.social

Imo, the point is: Hypertension guidelines are so complicated that even for a talk you are giving on the topic, you can easily be confused🤷‍♂️

Let‘s close the evidence gap for SGLT2i in ADPKD. Two large upcoming multicenter IITs in Europe will address this question and are described for the first time in this review. #STOPPKD #DAPAPKD

Just published in NDT : #SGLT2i for patients with #ADPKD – closing the evidence gap With experts from 🇩🇪🇳🇱🇯🇵🇺🇸🇫🇷 we review: ✅ Rationale for SGLT2i in ADPKD ✅ Preclinical and observational evidence ✅ Potential disease-specific benefits and risks ✅ Ongoing/upcoming trials, incl. #DAPAPKD & #STOPPKD

Can a #MedEd #Podcast improve your OSCE score? Yes—and now it’s published! This RCT by V.Dupont et al. shows that listening to #NephrOdio leads to: 🎧 +3.5 OSCE score boost 💪 Better self-perception of clinical skills (42% vs 16%) ✅ 96% would use the podcast again 👉🏼 doi.org/10.1186/s129...

I traded my U.S. medical career for a life in Canada. Here’s how the two health systems stack up. www.linkedin.com/posts/canada... via @canadahealthwatch.bsky.social

Can a #MedEd #Podcast improve your OSCE score? Yes—and now it’s published! This RCT by V.Dupont et al. shows that listening to #NephrOdio leads to: 🎧 +3.5 OSCE score boost 💪 Better self-perception of clinical skills (42% vs 16%) ✅ 96% would use the podcast again 👉🏼 doi.org/10.1186/s129...

Also note two large RCTs ongoing - or about to start - in France: bsky.app/profile/dgue...

Hey #NephSky‼️ A new @KIReports community blog on the use of #Flozins in #ADPKD …and on #Bluesky #NephJC at 9pm 3/25/25, we will discuss the first ever KDIGO ADPKD 2025 guidelines. A 1-2 punch 🥊 🥊 getting you up to date on ADPKD www.kireportscommunity.org/post/polycys...

we have reached the point where we seriously should avoid travelling to the US Sorry @asnkidney.bsky.social @ahascience.bsky.social @kidneycon.bsky.social #NephSky